Related Links Educational Materials About Clinical Trials Clinical Trials Questions to Ask Your Doctor Drug Information from MedlinePlus

Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Study of Perifosine in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

Basic Trial Information

Phase	Type	Status	Age	Sponsor	Protocol IDs
Phase II	Treatment	Completed	18 and over	NCI	ECOG-E1202 NCT00059982, E1202

Trial Description

Purpose:

Perifosine may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.

Phase II trial to study the effectiveness of perifosine in treating patients who have locally advanced, unresectable, or metastatic pancreatic cancer.

Eligibility:

• At least 18 years old
• Measurable disease
• No brain metastases
• No previous chemotherapy for pancreatic cancer
• More than 6 months since chemotherapy for any other disease
• At least 4 weeks since radiation therapy or surgery
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive perifosine by mouth every 6 hours for six doses. They will then receive perifosine once a day for as long as benefit is shown. Patients will be evaluated every 3 months for 3 years.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Eastern Cooperative Oncology Group

Robert Marsh, MD, Protocol chair		Ph: 352-273-7760
Caio Max Rocha Lima, MD, Protocol co-chair		Ph: 813-558-1667; 888-663-3488 Email: rochalcm@moffitt.usf.edu

Registry Information
Official Title		Phase II Trial Of Perifosine In Locally Advanced, Unresectable Or Metastatic Pancreatic Adenocarcinoma
Trial Start Date		2003-07-10
Registered in ClinicalTrials.gov		NCT00059982
Date Submitted to PDQ		2003-03-12
Information Last Verified		2004-08-26
NCI Grant/Contract Number		U10-CA21115

Back to Top